Literature DB >> 12023329

Cutting edge: competition for APC by CTLs of different specificities is not functionally important during induction of antiviral responses.

Hans Christian Probst1, Tilman Dumrese, Maries F van den Broek.   

Abstract

The hypothesis that T cell competition for access to APC influences priming of CTL responses is a controversial issue. A recent study using OVA as a model Ag supports this hypothesis and received considerable attention. However, using a comparable approach, we reached a different conclusion. We analyzed whether TCR transgenic T cells specific for lymphocytic choriomeningitis virus gp33-41/D(b) could inhibit the priming of endogenous responses against gp33-41 and against two other lymphocytic choriomeningitis virus glycoprotein-derived CTL epitopes. After priming with different stimuli, gp33-41/D(b)-specific TCR transgenic T cells reduced the endogenous gp33-41/D(b) response in a dose-dependent way, but all other endogenous responses were unaffected. Even when >10(6) TCR transgenic cells were combined with weak priming, no reduction of responses other than of those specific for gp33-41/D(b) was observed. Thus, competition for APC by CTLs of different specificities is not of functional relevance in antiviral immune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023329     DOI: 10.4049/jimmunol.168.11.5387

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Authors:  Christopher A Klebanoff; Hung T Khong; Paul A Antony; Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2005-02       Impact factor: 16.687

2.  CD8 T cell competition for dendritic cells in vivo is an early event in activation.

Authors:  Richard A Willis; John W Kappler; Philippa C Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

3.  A theory of immunodominance and adaptive regulation.

Authors:  Peter S Kim; Peter P Lee; Doron Levy
Journal:  Bull Math Biol       Date:  2010-10-01       Impact factor: 1.758

4.  Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.

Authors:  Joseph N Blattman; E John Wherry; Sang-Jun Ha; Robbert G van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

5.  CD8+ T-cell cross-competition is governed by peptide-MHC class I stability.

Authors:  Ian Galea; Jana Stasakova; Melanie S Dunscombe; Christian H Ottensmeier; Tim Elliott; Stephen M Thirdborough
Journal:  Eur J Immunol       Date:  2011-11-28       Impact factor: 5.532

6.  Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation.

Authors:  Dawn M Jelley-Gibbs; Deborah M Brown; John P Dibble; Laura Haynes; Sheri M Eaton; Susan L Swain
Journal:  J Exp Med       Date:  2005-09-05       Impact factor: 14.307

7.  High epitope expression levels increase competition between T cells.

Authors:  Almut Scherer; Marcel Salathé; Sebastian Bonhoeffer
Journal:  PLoS Comput Biol       Date:  2006-07-12       Impact factor: 4.475

8.  Cross-priming induces immunodomination in the presence of viral MHC class I inhibition.

Authors:  Elvin J Lauron; Liping Yang; Jabari I Elliott; Maria D Gainey; Daved H Fremont; Wayne M Yokoyama
Journal:  PLoS Pathog       Date:  2018-02-14       Impact factor: 6.823

9.  No evidence for competition between cytotoxic T-lymphocyte responses in HIV-1 infection.

Authors:  Helen R Fryer; Almut Scherer; Annette Oxenius; Rodney Phillips; Angela R McLean
Journal:  Proc Biol Sci       Date:  2009-09-23       Impact factor: 5.349

10.  Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination.

Authors:  Wolfgang Kastenmuller; Georg Gasteiger; Julian H Gronau; Robert Baier; Ronny Ljapoci; Dirk H Busch; Ingo Drexler
Journal:  J Exp Med       Date:  2007-08-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.